Showing posts with label pharmaceutical research. Show all posts
Showing posts with label pharmaceutical research. Show all posts

Monday, 24 May 2010

Afro Ng'ombe

Copyright Tool Helps Further Malaria Research

Copyright probably isn’t the first branch of intellectual property that comes to mind when thinking about malaria prevention.  The medication itself is covered by patents, the brand name by trademark.  But what many of us might not realize is that the information discovered during research, the data sets, diagrams and descriptions of findings, are often covered by copyright.

In a move to help facilitate anti-malarial research, GlaxoSmithKline has released its chemical structure and data findings under CC0 (Creative Commons Zero), a waiver that effectively places this information in the public domain. 

The dataset contains the structures and screening data for over 13,500 compounds confirmed to inhibit parasite growth by more than 80% at 2 uM concentration.

Novartis-GNF and St. Jude Children’s Research Hospital have also released antimalarial research data sets under other open access licenses.  Releasing the datasets under open licenses or into the public domain (in GSK’s case) should enable others to conduct research that builds off the work already done without having to redo what GSK, GNF and St. Jude already did.

More information on the released data here.

Read More

Tuesday, 28 October 2008

Darren Olivier

Botswana and South Africa to benefit from Pharma grant

A McGill University parasitology researcher (Dr. Timothy Geary) has received a $100,000 grant from the Gates Foundation to help establish locally controlled pharmaceutical research programs in Botswana and South Africa.

"Over the last 15 or 20 years there has been tension between the industrialized north and the developing south over this issue," he continued. "There was a sense in the south that people from the north were simply looting this resource. We called it bioprospecting; they called it 'biopiracy,' which caused obvious problems in negotiating access and contracts." Moreover, said Geary, philanthropic attempts to establish a pharmaceutical research base in Africa often fail because they lack the crucial element of sustainability: Donations of expensive high-tech equipment typically do not take long-term maintenance into account, for example.

According to Geary, "Africans will do the research and own the intellectual property. This creates sustainability: if you can license the products of your screening, you have a revenue stream."... "The other goal, that's very important, is that Africans should be leading this program in the very short term, two to three years. I hope to make myself irrelevant." (Source Eurekalert)

The cause seesm both sensible and noble but wonders how far $100,000 will go. Hopefully the revenue streams start to materialise fairly quickly and the programs are able to benefit from other funding or government initiatives.
Read More